「Trump Account」 to Allow Billionaires to Donate Stock Directly
BlockBeats News, May 6th. According to The New York Times, White House and U.S. Treasury officials have been in internal discussions about expanding the reach of the "Trump Account" (officially known as the 530A Account). The current discussions include allowing the world's wealthiest individuals to donate their company stocks. The Trump Account currently only allows cash investments in diversified index funds and prohibits stock donations. This concept aims to tap into the unrealized wealth of billionaires like Musk or Huang Renjun. If the rules are modified, Musk would be able to donate Tesla or SpaceX stocks directly, and Huang Renjun could donate Nvidia stocks. Children, instead of slow and steady returns from index funds, would be able to hold long-term positions in high-growth large-cap tech stocks and potentially reap huge gains.
Donors would be able to transfer high-value stocks worth billions of dollars without triggering capital gains tax, while receiving full charitable donation tax deductions based on the fair market value of the stocks, further reducing their tax burden. However, this idea has sparked debates within the Treasury Department. The limitation of the Trump Account to diversified index funds was originally intended to shield children from the impact of market volatility. To amend the current rules, regulatory changes would be required, potentially necessitating legislative action. (Kryptonite)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
